BioCorRx Reports Business Update for 2023
April 02, 2024 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
February 28, 2024 10:49 ET
|
BioCorRx Inc
ANAHEIM, CA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related...
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
February 08, 2024 09:52 ET
|
BioCorRx Inc
ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
Global $39B+ Addiction Disorders Drugs Market Forecast, 2030: Regional Trends and Revenue Insights by Drug Type, Treatment Option, and End-user with a Comprehensive Global Competitive Assessment
January 29, 2024 09:11 ET
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Addiction Disorders Drugs Market by Drug Type (Alcohol, Marijuana, Prescription & Over-the-Counter Medications), Treatment (Counseling &...
Global Substance Abuse (Alcohol, Cocaine, Marijuana, Nicotine) Treatment Market Report 2024-2030: Emerging Trends and Regional Insights for Products and Treatment Options
January 29, 2024 09:07 ET
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Substance Abuse Treatment Market by Substance Abuse Type (Alcohol Addiction, Cocaine, Marijuana), Product (Behavioral Treatment, Drugs),...
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
January 09, 2024 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
Comprise named top agency in several business, PR and marketing awards programs
December 19, 2023 06:00 ET
|
Comprise
Boulder, Colo., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Comprise® solidified its status as a leading communications agency delivering integrated public relations and digital marketing services with the...
BioCorRx Reports Business Update for the Third Quarter of 2023
November 14, 2023 12:52 ET
|
BioCorRx Inc
ANAHEIM, CA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
August 15, 2023 09:00 ET
|
BioCorRx Inc
Company Hopes in 30 Days to Begin Making Its Drug Candidate Available to Help Patients and Address Public Health Crisis ANAHEIM, CA, Aug. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire...
BioCorRx Reports Business Update for the Second Quarter of 2023
August 14, 2023 16:34 ET
|
BioCorRx Inc
On Track to Meet 2023 Regulatory Milestones ANAHEIM, CA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative...